Amphetamine/Dextroamphetamine

Summary

Amphetamine/Dextroamphetamine (CHEMBL5095505) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 405.6 Da · C27H39N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095505
Name	Amphetamine/Dextroamphetamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	166625415
Molecular formula	C27H39N3
Molecular weight	405.6
InChIKey	DUKHFSGXIHAISL-QXGOIDDHSA-N

SMILES: C[C@@H](CC1=CC=CC=C1)N.C[C@@H](CC1=CC=CC=C1)N.CC(CC1=CC=CC=C1)N

IUPAC name: 1-phenylpropan-2-amine;bis((2S)-1-phenylpropan-2-amine)

Parent form; salt/anhydrous children: CHEMBL5095048

Patent coverage: 29 distinct patent families (100 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01478113	Not specified	TERMINATED	Stimulant Enhancement of Well-Being Therapy for Depression

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).